-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2021, the domestic innovative medicine industry has ushered in rapid development under a series of favorable factors such as favorable policies, the influx of talents, and the overweight of capital
.
And with the momentum of domestic innovative drugs, the achievements of major pharmaceutical companies in innovative drugs have also begun to appear.
A batch of new drugs with obvious clinical value and meeting clinical needs are accelerating clinical trials and even listing, bringing more patients to the market.
Come to the gospel
.
Among them, it is worth mentioning that in the recent past, some pharmaceutical companies have successively applied for the clinical and marketing of 7 new drugs in the past week
.
On December 24, the clinical application of Hengrui Medicine's 2 Class 1 new drugs was accepted by CDE, namely SHR-1816 injection and SHR-1501 for injection; in addition, the first company submitted 10% fat emulsion (OO )/5.
5% amino acid (15)/glucose (20%) injection was also approved on the same day
.
On the 20th, Hengrui Medicine has another clinical application for three new category 1 drugs and one category 2.
4 new drug that have been accepted by the CDE
.
Among them, Class 1 new drugs are therapeutic biological products SHR-1316 injection, SHR-A1811, SHR0302 for injections; Class 2.
4 new drugs are pyrrotinib maleate tablets
.
In addition, on the 17th, the clinical application of HRS-2261 tablets of Hengrui Medicine has also been approved
.
From an overall point of view, among the 7 drugs, there are 6 Class 1 new drugs.
It is worth mentioning that SHR-1816 injection and HRS-2261 tablets are the first clinical applications submitted in China
.
In this regard, the industry believes that, for many years, Hengrui Medicine has been focusing on the development of anti-tumor, diabetes, cardiovascular, autoimmune diseases and other fields, and from the current approval of new drug clinical trials, it has developed independent technology The results of continuously enhancing the core competitiveness of the enterprise have begun to appear
.
At present, in addition to the above drugs, Hengrui Medicine also holds 8 innovative drugs approved for marketing
.
From the beginning of September to December 20, in less than four months, Hengrui Pharmaceuticals also issued 5 announcements of drug registration certificates, 26 announcements of approval of clinical trials, and 3 announcements of conformity evaluation.
.
According to data, Hengrui Medicine currently has 108 innovative drugs (excluding new indications for the development of new drugs on the market), including new drugs introduced through cooperation, in the clinical application and above stages, many of which are Class 1 new drugs
.
The emergence of a large number of new drugs is actually inseparable from large R&D investment
.
It is understood that with the continuous acceleration of Hengrui Pharmaceutical's deployment of innovative drug clinical trials, the company's R&D investment has been continuously increasing
.
According to statistics, in 2018, 2019 and 2020, Hengrui Pharmaceutical’s R&D expenses will be 2.
7 billion, 3.
9 billion and 5 billion yuan; in the first three quarters of 2021, Hengrui’s cumulative R&D expenses increased by 23.
86% year-on-year.
It has reached 4.
142 billion yuan, accounting for 20.
51% of sales revenue
.
Among them, R&D investment in the third quarter reached 1.
561 billion yuan
.
According to the industry, Hengrui Pharmaceutical's continuous increase in the rate of R&D expenses fully demonstrates its strategic focus in the development of new drugs
.
The industry predicts that in the future, with Hengrui's continuous and high-quality development in innovation, it will effectively realize the accelerated transformation of innovation results, produce more and better innovative drugs, and play an active leading role in the transformation and upgrading of China's biomedical industry.
And further contribute to the realization of the 2030 Healthy China Strategy
.
.
And with the momentum of domestic innovative drugs, the achievements of major pharmaceutical companies in innovative drugs have also begun to appear.
A batch of new drugs with obvious clinical value and meeting clinical needs are accelerating clinical trials and even listing, bringing more patients to the market.
Come to the gospel
.
Among them, it is worth mentioning that in the recent past, some pharmaceutical companies have successively applied for the clinical and marketing of 7 new drugs in the past week
.
On December 24, the clinical application of Hengrui Medicine's 2 Class 1 new drugs was accepted by CDE, namely SHR-1816 injection and SHR-1501 for injection; in addition, the first company submitted 10% fat emulsion (OO )/5.
5% amino acid (15)/glucose (20%) injection was also approved on the same day
.
On the 20th, Hengrui Medicine has another clinical application for three new category 1 drugs and one category 2.
4 new drug that have been accepted by the CDE
.
Among them, Class 1 new drugs are therapeutic biological products SHR-1316 injection, SHR-A1811, SHR0302 for injections; Class 2.
4 new drugs are pyrrotinib maleate tablets
.
In addition, on the 17th, the clinical application of HRS-2261 tablets of Hengrui Medicine has also been approved
.
From an overall point of view, among the 7 drugs, there are 6 Class 1 new drugs.
It is worth mentioning that SHR-1816 injection and HRS-2261 tablets are the first clinical applications submitted in China
.
In this regard, the industry believes that, for many years, Hengrui Medicine has been focusing on the development of anti-tumor, diabetes, cardiovascular, autoimmune diseases and other fields, and from the current approval of new drug clinical trials, it has developed independent technology The results of continuously enhancing the core competitiveness of the enterprise have begun to appear
.
At present, in addition to the above drugs, Hengrui Medicine also holds 8 innovative drugs approved for marketing
.
From the beginning of September to December 20, in less than four months, Hengrui Pharmaceuticals also issued 5 announcements of drug registration certificates, 26 announcements of approval of clinical trials, and 3 announcements of conformity evaluation.
.
According to data, Hengrui Medicine currently has 108 innovative drugs (excluding new indications for the development of new drugs on the market), including new drugs introduced through cooperation, in the clinical application and above stages, many of which are Class 1 new drugs
.
The emergence of a large number of new drugs is actually inseparable from large R&D investment
.
It is understood that with the continuous acceleration of Hengrui Pharmaceutical's deployment of innovative drug clinical trials, the company's R&D investment has been continuously increasing
.
According to statistics, in 2018, 2019 and 2020, Hengrui Pharmaceutical’s R&D expenses will be 2.
7 billion, 3.
9 billion and 5 billion yuan; in the first three quarters of 2021, Hengrui’s cumulative R&D expenses increased by 23.
86% year-on-year.
It has reached 4.
142 billion yuan, accounting for 20.
51% of sales revenue
.
Among them, R&D investment in the third quarter reached 1.
561 billion yuan
.
According to the industry, Hengrui Pharmaceutical's continuous increase in the rate of R&D expenses fully demonstrates its strategic focus in the development of new drugs
.
The industry predicts that in the future, with Hengrui's continuous and high-quality development in innovation, it will effectively realize the accelerated transformation of innovation results, produce more and better innovative drugs, and play an active leading role in the transformation and upgrading of China's biomedical industry.
And further contribute to the realization of the 2030 Healthy China Strategy
.
